Effectiveness of fidaxomicin in preventing recurrence after initial community-associated Clostridioides difficile infection

Using population-based surveillance from 2020 to 2024, we examined recurrence through 180 days among adults with initial community-associated Clostridioides difficile infection (CDI). Fidaxomicin was associated with a 50% lower risk of recurrence compared with vancomycin. These findings are consistent with current guideline recommendations and are relevant to outpatient management of initial CDI.